chondroitin-sulfates and Lymphoma--Large-B-Cell--Diffuse

Sulfated glycosaminoglycans are known to inhibit mammalian acid-active sialidase. Although the inhibition depends clearly on the presence of sulfate groups on these macromolecules, there was no information on the intrinsic inhibitory potency of inorganic sulfate. In this study, we demonstrate that inorganic sulfates inhibit acid-active Mu-Neu5Ac sialidase of U937 cells. This inhibition was found to be reversible and it appeared to be of the mixed competitive type. Sulfate-induced inhibition was also observed in other cells as well as with other substrates such as sialyl lactose and bovine mixed brain gangliosides. We conclude that the intrinsic inhibitory potency of sulfate groups may be significantly involved in the inhibition of acid-active sialidase by sulfated glycosaminoglycans. In addition, inorganic sulfate by its apparent potency to selectively inhibit acid sialidases might constitute an interesting tool for the characterisation of the minor forms of sialidases occurring in mammalian cells.

Topics: Ammonium Sulfate; Chondroitin Sulfates; Humans; Lymphoma, Large B-Cell, Diffuse; Neuraminidase; Subcellular Fractions; Sulfates; Tumor Cells, Cultured

Topics: Animals; B-Lymphocytes; CD4-Positive T-Lymphocytes; Cell Differentiation; Chondroitin Sulfates; Cytokines; Dextran Sulfate; Drug Synergism; Interferon-gamma; Interleukin-4; Interleukins; Lymph Nodes; Lymphocyte Activation; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred Strains; Mice, Mutant Strains; Peritoneal Cavity; Spleen; Splenic Neoplasms; Tumor Stem Cell Assay

Glycosaminoglycans (heparins, dermatan sulfate, chondroitin sulfate) with different structures and physicochemical properties were evaluated for their capacity to influence proliferation and differentiation of U-937 cell line. The contrasting and specific effects of glycosaminoglycans (depending on their structures and properties) on a leukemia cell line could help explain the regulation of proliferative and/or differentiative processes of hematopoietic cells in order to clarify the control of development and differentiation of hematopoietic progenitor cells by bone marrow extracellular matrix. Heparin from beef intestinal mucosa, heparan sulfate from beef spleen, dermatan sulfate from beef intestinal mucosa, and chondroitin sulfate from bovine trachea were extracted and purified, and their purity, structures, and physicochemical properties were evaluated. Fast-moving heparin was obtained by its selective precipitation as barium salt, and partially desulfated and re-N-sulfated heparin was produced by chemical modifications. Different glycosaminoglycans were tested to evaluate their effects on proliferation and differentiation processes of a monoblastic leukemia cell line (U-937). Heparin and derivatives (from 0.1 to 100 micrograms/ml) inhibit cell proliferation; heparan sulfate does not produce modifications, while chondroitin sulfate and dermatan sulfate (from 0.01 to 100 micrograms/ml) significantly stimulate cell growth. Cell differentiation was evaluated by cytoenzymatic determination of alpha-naphthyl butyrate esterase and by fluorescein-labeled anti-HLA-DR, anti-CD11b, and anti-CD14 antibodies. Nitro blue tetrazolium reduction and phagocytosis were also evaluated. Heparin and derivatives significantly increase U-937 differentiation. Heparin sulfate has no effect, while chondroitin sulfate and, to a lesser extent, dermatan sulfate, induce a strong decrease of differentiative markers. The regulation of U-937 cell properties appears to be related to charge density and to the amount of N-sulfate and N-acetyl groups. In particular, glycosaminoglycans with lower sulfate-to-carboxyl ratios and N-sulfate group percentages (chondroitin sulfate and dermatan sulfate) stimulate proliferation and produce a decrease of differentiative markers; on the contrary, polysaccharides with high charge density and N-sulfate group amounts (heparin and derivatives) inhibit U-937 proliferation and induce terminal differentiation. A previous paper (N. Volpi, L. Bolognani, A. C

Topics: Animals; Carbohydrate Conformation; Carbohydrate Sequence; Cattle; Cell Differentiation; Cell Division; Cell Line; Chondroitin Sulfates; Chromatography, High Pressure Liquid; Dermatan Sulfate; Disaccharides; DNA, Neoplasm; Glycosaminoglycans; Heparin; Heparitin Sulfate; Humans; Intestinal Mucosa; Leukemia; Lymphoma, Large B-Cell, Diffuse; Molecular Sequence Data; Molecular Structure; Structure-Activity Relationship; Thymidine; Tumor Cells, Cultured

The effect of various glycosaminoglycans on the growth of cultured Tawa sarcoma cells (CTS cells) were determined under both fast and slow growth conditions. Hyaluronic acid, chondroitin, chondroitin 4-sulfate, and chondroitin 6-sulfate (all of which have only one type of uronic acid, glucuronic acid) inhibited the growth of CTS cells during fast growth and accelerated it during slow growth. Both keratan sulfate and keratan polysulfate (containing galactose) inhibited the growth of CTS cells during both growth conditions. Only glycosaminoglycans containing iduronic acid (heparin, heparan sulfate, and dermatan sulfate) accelerated the growth of the cells during fast growth. However, heparin inhibited the growth during slow growth while heparan sulfate and dermatan sulfate accelerated it. Growth regulation seems to require complete structural integrity of the glycosaminoglycans. The component subunits alone lack such activity when not linked together.

Topics: Animals; Cell Division; Chondroitin Sulfates; Culture Media, Conditioned; Dermatan Sulfate; Extracellular Matrix; Glycosaminoglycans; Growth Substances; Heparin; Heparitin Sulfate; Hyaluronic Acid; Keratan Sulfate; Lymphoma, Large B-Cell, Diffuse; Rats; Sarcoma, Experimental; Tumor Cells, Cultured

A monoblastic cell line U-937 (clone 4), was induced to differentiate along the monocytoid lineage by 12-O-tetradecanoylphorbol-13-acetate (TPA), retinoic acid (RA), and vitamin D3 (VD3). By immunochemical and morphological criteria the cells were found to differentiate into macrophage-like cells in the presence of all three inducers. The expression of proteoglycans was investigated in control cultures and in cells differentiated in the presence of both TPA, RA, and VD3. The cells were labeled with [35S]sulfate and cell and medium-associated 35S-macromolecules were either solubilized in sodium dodecyl sulfate or subjected to proteolytic digestion. By use of chondroitinase ABC digestions and deaminative cleavage at pH 1.5 it was demonstrated that all cell cultures incorporated [35S]sulfate exclusively into chondroitin sulfate proteoglycan (CSPG). The expression of CSPG was found to decrease with differentiation to 60% in the presence of TPA, 67% in RA, and 40% in VD3 of control cultures on a cellular basis. The CSPG synthesized was consistently recovered from the medium fractions, whereas free glycosaminoglycan (GAG) chains were found in the cell fraction in all the cell cultures. GAG chains from both control and TPA-, RA-, and VD3-induced cultures were found to be exclusively of the chondroitin 4-sulfate type. However, the CSPGs from RA- and VD3-treated cells were found to differ in molecular size from those of control and TPA-induced cultures, as judged by Sepharose CL-6B gel chromatography. This difference in macromolecular properties following the induced differentiation of the monoblastic cells into macrophage-like cells was found to reside in expression of CSPGs (in the presence of RA and VD3) with smaller GAG chains. Control cells and TPA-induced cells synthesized CSPGs with GAG chains of approximate Mr of 30,000, contrasted by approximate Mr of 17,000 and 16,000 in RA- and VD3-induced cells, respectively. Accordingly, all three agents used in this study were found to induce differentiation of the U-937-4 cells and a decrease in the expression of CSPG, but only RA and VD3 were found to influence the structure of the proteoglycans synthesized.

Topics: Cell Differentiation; Cholecalciferol; Chondroitin; Chondroitin Sulfates; Glycosaminoglycans; Humans; Lymphoma, Large B-Cell, Diffuse; Monocytes; Proteoglycans; Tetradecanoylphorbol Acetate; Tretinoin